Strix
26.1K

CVE-2014-6721

UnknownEPSS 0.66%

Last modified

CVE-2014-6721 is a vulnerability of currently unknown severity. The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.. EPSS estimates a 0.66% chance of exploitation in the next 30 days.

Description

The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.

Metrics

EPSS Probability
0.66%

46.7th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

Affected Software

VendorProductVersions
PharmaguidelinePharmaguideline1.2.0

References

Timeline

Published
Last Modified
Status
Modified

Frequently Asked Questions

What is CVE-2014-6721?
The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.
How severe is CVE-2014-6721?
Severity scoring for CVE-2014-6721 is pending analysis. The EPSS model estimates a 0.66% probability of exploitation in the next 30 days.
How do I fix CVE-2014-6721?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

Are you affected by CVE-2014-6721?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST